June 25, 2022

Medical Trend

Medical News and Medical Resources

The 3rd EU country stopped Oxford-AstraZeneca COVID-19 vaccine

The 3rd EU country stopped Oxford-AstraZeneca COVID-19 vaccine

 

The 3rd EU country stopped Oxford-AstraZeneca COVID-19 vaccine.  As “nationals are unwilling to vaccinate”, another EU country has stopped the Oxford-AstraZeneca vaccine. 

European people’s rejection of the Oxford-AstraZeneca vaccine has intensified.

On the evening of May 17, Austria announced that it would discontinue the Oxford-AstraZeneca COVID-19 vaccine jointly developed by the United Kingdom/Sweden, making it the third country in Europe to discontinue the vaccine after Denmark and Norway.

Austria announced that due to supply problems, it has stopped continuing to vaccinate the Oxford-AstraZeneca vaccine in Austria. In the future, Austria will only rely on vaccines from Biontech/Pfizer and Moderna and Johnson & Johnson for vaccination against viruses. However, those who have received the first shot will continue to receive the second shot of Oxford-AstraZeneca vaccine, and the current stock dose of the second shot is sufficient.

 

Austria decides to stop the Oxford-AstraZeneca vaccine

Among European countries, Austria’s vaccination situation is relatively good. 1/3 of the country’s population has been vaccinated with Oxford-AstraZeneca vaccine. Together with Pfizer and Moderna vaccines, the proportion of at least one dose is about half of the population.

Austrian Health Minister Wolfgang Mukstein said that the reason for discontinuing the Oxford-AstraZeneca vaccine is not just because the vaccine may cause side effects such as blood clotting and thrombosis, and because of the Oxford-AstraZeneca vaccine between the United Kingdom and the European Union. The controversy over delayed delivery is that “many Austrian nationals are unwilling to receive this vaccine.” Mukstein said that the first dose of Oxford-AstraZeneca vaccine is still open until early June.

Only three vaccines, namely Oxford-AstraZeneca, Pfizer and Moderna, are approved by Austria and can be vaccinated in the country. As Austria announced this time is “discontinued”, it will mainly rely on the other two vaccines in the future. It is reported that Austria has ordered vaccines delivered in 2022 and 2023 from these two vaccine suppliers respectively.

Due to side-effect disputes, and also due to the contradiction in the delivery of vaccines between Britain and Europe, in mid-March, 20 EU countries have announced the “suspend” vaccinations of Oxford-AstraZeneca. In addition, Asian countries such as Indonesia also once “suspended”.

However, after the European Medicines Agency and the World Health Organization have successively issued expert opinions that “the side effects of coagulation and thrombosis are quite rare, and the benefits of immunization brought by vaccination are far greater than the risk of coagulation and thrombosis”, countries have once cancelled the “suspend”.

However, with the emergence of deaths due to side effects one after another, on April 14, Denmark became the first country in Europe and the world to “stop” the Oxford-AstraZeneca vaccine. On May 12, Norwegian Prime Minister Solberg announced that Norway had become the second country to “suspend”. Today, Austria has increased the number of countries that “stopped” the vaccine to three.

 

Is the deactivation “for a reason” or “use of the question”?

A poll in Italy in mid-March showed that 65% of the respondents wanted the right to choose their own vaccination varieties. Among them, 46% wanted Pfizer vaccines and 22% in Moderna. The once-hot Oxford-AstraZeneca vaccine selection ratio ( 9%) is not even as good as Russia’s “Satellite-V” (10%).

Initially, countries with a large number of Oxford-AstraZeneca vaccines are still working hard to restore the impact. For example, Canada has not only set up “on-the-go” vaccines in communities with high epidemics, but only provides Oxford-AstraZeneca vaccines. Prime Minister Trudeau Many. He Jin, the governor of British Columbia, also publicly “calls the name” to vaccinate the vaccine, trying to play an exemplary role.

But the public’s rejection of the Oxford-AstraZeneca vaccine has intensified. In early May, the British Joint Committee on Vaccines and Immunization announced that adults under the age of 40 can choose other vaccinations other than the Oxford-AstraZeneca vaccine. Although this announcement cannot be said to be the last straw to crush the camel, it is indeed correct. The “Oxford-AstraZeneca vaccine panic” contributed to the flames.

Some countries have previously ordered a large number of Oxford-AstraZeneca vaccines produced in India during the “vaccine shortage”. Recently, India has a major outbreak and India is temporarily unable to supply it.

To make matters worse, the Johnson & Johnson vaccine, which was independently developed in the United States and also uses the adenovirus principle, has recently seen similar cases. This not only forces many countries to stop or postpone the approval of the Johnson & Johnson vaccine, but also makes the Oxford-AstraZeneca vaccine more “suspicious.”

 

What is the outlook for the Oxford-AstraZeneca vaccine?

On a global scale, the vaccination rate in many third world countries is still in the single digits. If adenovirus vaccines are rejected, inactivated vaccines and mRNA vaccines will not be able to fill the huge gap in a short time.

However, one of the important reasons for the stagnation of vaccination rates in industrialized countries and regions such as Japan before was the “public’s’Oxford-AstraZeneca vaccine panic'”. This time, the Austrian Minister of Health directly regarded “popular rejection” as As the reason for “deactivation”.

But Oxford Biomedical, the manufacturer of the Oxford-AstraZeneca vaccine, is still bullish: before they criticized the “weak and retreat” Canadians “waiting to be killed by the Indian variants” and accused the Europeans who rejected the company’s vaccines for being short-sighted.

The problem is that the production capacity of mRNA vaccines such as Pfizer is gradually “slowing down”, and inactivated vaccines such as China National Medicines have also gained momentum after receiving emergency authorization from the WHO and good data support from many countries. What is the future prospect of the Oxford-AstraZeneca vaccine? What?

After Austria became the third “permanent suspension” country, some people have begun to reflect on the crisis public relations caliber that EMA, WHO, and Oxford Biomedical Company have insisted that “side effects are rare and the risk is far less than the epidemic”.

 

(source:internet, reference only)


Disclaimer of medicaltrend.org